Share

January 2020; 7 (1) Clinical/Scientific NotesOpen Access

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS

Leoni Rolfes, Steffen Pfeuffer, Tobias Ruck, Susanne Windhagen, Ilske Oschlies, Hermann-Joseph Pavenstädt, Linus Angenendt, Heinz Wiendl, Julia Krämer, Sven G. Meuth
First published November 8, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000638
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
679

Share

This article has a correction. Please see:

Article Figures & Data

Figures

  • Figure
    Figure Diagnostic work-up and treatment regimes in an alemtuzumab-treated patient with RRMS developing idiopathic multicentric Castleman disease

    (A–E) Charts show the course of CRP, hemoglobin, platelets, white blood cell count, and blood urea nitrogen since the initial presentation during hospitalization. Time points and length of different treatment regimens are outlined in (A) (♦: IV methylprednisolone 250 mg, cumulative dose 2,750 mg; •: immunoadsorption; *: IVIG single dose, 1 mg/kg). Arrows represent platelet (B) and erythrocyte concentrate (C) transfusions and hemodialysis (E). (F) Abdominal CT scan outlining extensive abdominal (red arrows) and inguinal (yellow arrows) lymphadenopathy. (G–H) Axial thoracic and abdominal CT scan indicating polyserositis with pleural (G: yellow arrows) and pericardial (G: red arrows) effusions and ascites (F: yellow arrows) as well as hepatosplenomegaly (F: red arrows). (I) H&E staining of bone marrow puncture displaying megakaryocytosis. (J–K) Mediastinal lymph node biopsy consistent with iMCD plasma cell type. (J) Haematoxylin and eosin stain displaying regressive germinal centers (blue arrows), with small vessels reaching into germinal centers (“lollipop vessels,” black arrows). (K) Giemsa staining displaying interfollicular proliferation of plasma cells (black arrows).

  1. Leoni Rolfes, MD*,
  2. Steffen Pfeuffer, MD,
  3. Tobias Ruck, MD,
  4. Susanne Windhagen, MD,
  5. Ilske Oschlies, MD,
  6. Hermann-Joseph Pavenstädt, MD,
  7. Linus Angenendt, MD,
  8. Heinz Wiendl, MD,
  9. Julia Krämer, MD* and
  10. Sven G. Meuth, MD, PhD*
  1. From the Clinic of Neurology with Institute of Translational Neurology (L.R., S.P., T.R., H.W., J.K., S.G.M.), University Hospital Münster; Department of Neurology and Neurological Rehabilitation (S.W.), Hospital Osnabrück, Am Finkenhügel 1; Department of Pathology (I.O.), Hematopathology Section and Lymph Node Registry, University-Hospital Schleswig-Holstein, Campus Kiel; Department of General Internal Medicine (H.-J.P.), Nephrology, Hypertensiology, and Rheumatology, University Hospital Münster; and Department of Hematology (L.A.), Hemostaseology, Oncology, and Pneumology, University Hospital Münster, Germany.
  1. Correspondence
    Dr. Rolfes leoni.rolfes{at}ukmuenster.de
Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. (1) Merck Serono, travel reimbursements (2) Sanofi Genzyme, travel reimbursements

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. Commercial entity: Travel grants by Sanofi Genzyme, Merck, Biogen, Mylan

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. Commercial entity: Research support from DIAMED ans Merck Serono

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. Society: Research support from the German Multiple Sclerosis Society (DMSG)

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. TR served on a scientific advisory board for Genzyme, Merck and Novartis.

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. TR has received travel expenses from Genzyme and Novartis and has received honoraria for lecturing from Genzyme, Biogen and Teva.

Editorial Boards:

  1. Guest associate editor for Frontiers in Neurology.

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. TR has received financial research support from Genzyme and Novartis.

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. Supported by the German Ministry of Education, Science, Research and Technology (01GI1603D, to T.R. and S.G.M.; FKZ01FI1603A to HW, LK, and CCG)

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. Honoraria for speaking engagements from Bayer Vital, Biogen, Merck-Serono, Novartis Pharma and TEVA-Pharma.

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. (1) Biogen (2) Evgen (3) Genzyme (3) MedDay Pharmaceuticals (4) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Aventis

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. (1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Genzyme (10) TEVA (11) WebMD Global

Editorial Boards:

  1. (1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. (1) Abbvie (2) Actelion (3) Biogen (4) IGES (5) Johnson & Johnson (6) Novartis (7) Roche (8) Sanofi-Aventis (9) Swiss Multiple Sclerosis Society

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. (1) Biogen (2) GlaxoSmithKline GmbH (3) Roche Pharma AG (4) Sanofi-Genzyme.

Research Support, Government Entities:

  1. (1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. (1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children’s Foundation

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Scientific Advisory Boards:

  1. (1) German association for Multiple Sclerosis (2) German Society for Neurology (DGN)(3) Neurology Trust (4) Center for Clinical Studies (ZKS) (5) Max Planck Society

Gifts:

  1. NONE

Funding for travel or speaker honoraria:

  1. Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.

Editorial Boards:

  1. (1) PLoS One (editor) (2) DGNeurologie, founding member editorial board

Patents:

  1. (1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4 – 1402) (3)"NR2B selective NMDA-receptor Antagonists for Treatment of immune-mediated inflammatory diseases” (Reference number: PCT/EP2016/069975)

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. Research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.

Research Support, Government Entities:

  1. Research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. Research is funded by Else Kröner Fresenius Foundation, Hertie Foundation

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Alemtuzumab is an efficacious therapy for active relapsing-remitting MS (RRMS), but its use is complicated by the potential development of secondary autoimmunity.1 Recent data from phase 3 extension studies confirm thyroid autoimmunity as the most abundant entity of secondary autoimmunity found in up to 30%–40% of treated patients, with most events mild or moderate in severity. Data also show low rates of previously known autoimmune phenomena, such as immune thrombocytopenia and nephropathy.2 However, further entities including sarcoidosis, vitiligo, and hemophagocytic lymphohistiocytosis (HLH) have been described in real-world cohorts.3 Here, we present a case of another lymphoproliferative syndrome, namely idiopathic multicentric Castleman disease (iMCD), after alemtuzumab treatment.

Case report

A 30-year-old Caucasian man was first diagnosed with RRMS in 2003. After initial interferon-β1a and natalizumab (61 infusions) treatment, he received 2 courses of alemtuzumab (December 2014 and December 2015) because of persistent disease activity. Infusions were administered without complications, and disease activity stabilized over time. The patient developed Graves' disease 24 months after alemtuzumab initiation.

In April 2018, he presented to his local hospital with fatigue, fever, dyspnea, and thoracic and abdominal pain. Clinical examination revealed generalized lymphadenopathy, hepatosplenomegaly, and edema. Sonography indicated pleural and pericardial effusion and ascites suggestive of polyserositis. He developed pancytopenia and showed elevated serum C-reactive protein (CRP, figure, A and B) and hypoalbuminemia (2.24 g/dL). A mesenteric lymph node (LN) biopsy was performed and was deemed inconclusive.

Figure
Figure Diagnostic work-up and treatment regimes in an alemtuzumab-treated patient with RRMS developing idiopathic multicentric Castleman disease

(A–E) Charts show the course of CRP, hemoglobin, platelets, white blood cell count, and blood urea nitrogen since the initial presentation during hospitalization. Time points and length of different treatment regimens are outlined in (A) (♦: IV methylprednisolone 250 mg, cumulative dose 2,750 mg; •: immunoadsorption; *: IVIG single dose, 1 mg/kg). Arrows represent platelet (B) and erythrocyte concentrate (C) transfusions and hemodialysis (E). (F) Abdominal CT scan outlining extensive abdominal (red arrows) and inguinal (yellow arrows) lymphadenopathy. (G–H) Axial thoracic and abdominal CT scan indicating polyserositis with pleural (G: yellow arrows) and pericardial (G: red arrows) effusions and ascites (F: yellow arrows) as well as hepatosplenomegaly (F: red arrows). (I) H&E staining of bone marrow puncture displaying megakaryocytosis. (J–K) Mediastinal lymph node biopsy consistent with iMCD plasma cell type. (J) Haematoxylin and eosin stain displaying regressive germinal centers (blue arrows), with small vessels reaching into germinal centers (“lollipop vessels,” black arrows). (K) Giemsa staining displaying interfollicular proliferation of plasma cells (black arrows).

He was referred to our clinic. Repeated serologic testing for autoimmune, paraneoplastic, and infectious causes remained inconspicuous, especially regarding antinuclear antibodies and herpesvirus (including human herpesvirus (HHV)-8 and HIV PCR in peripheral blood). Whole-body 18F-FDG PET/CT, bronchoscopy, and gastro-/colonoscopy provided no further explanations. Persistent disseminated lymphadenopathy, polyserositis, and organomegaly were detected through CT (figure, F–H). An axillary LN biopsy was performed 3 weeks after the initial presentation, but changes were nonspecific despite extensive immunohistochemistry and clonality analysis. Bone marrow puncture revealed increased megakaryocytosis (figure, I).

After immunosuppressive therapy with high-dose IV methylprednisolone (IVMPS, figure, A♦) and immunoadsorption (IA, figure, A•), inflammatory activity decreased and blood cell counts rose again. Pleural and ascites punctures had to be performed less frequently.

However, 28 days after symptom onset, the patient rapidly redeteriorated with increasing serum CRP-levels and re-emerging cytopenia, especially thrombocytopenia refractory to IV immunoglobulins (figure, A and B*). Because of intrathoracic bleeding, he required multiple erythrocyte and platelet transfusions and an emergency thoracotomy. Thereafter, the patient was referred to the intensive care unit because of renal failure (predominantly caused by systemic inflammation (procalcitonin 18 ng/mL) and third spacing) and underwent continuous hemodialysis under which blood cell counts, effusions, edema, and retention parameters slowly recovered (figure, A–E). A LN extracted during thoracotomy revealed findings typical for Castleman disease, including hyperplasia, germinal center regression, plasma cell expansion, and hyalinized vessels (figure, J and K). HHV-8 immunohistochemical staining was negative. Ascites interleukin (IL)-6 levels were strongly increased (4,030 pg/mL, reference: <3 pg/mL, otherwise published value: 4,440 pg/mL4). Consequently, a diagnosis of iMCD with TAFRO (Thrombocytopenia, Anasarca, MyeloFibrosis, Renal failure, Organomegaly) subtype (typical histopathologic findings, HHV-8 negative immunohistochemistry, thrombocytopenia (figure, B), fever, organomegaly, absence of hypergammaglobulinemia (0.8 g/dL), lymphadenopathy, and hyperplasia of megakaryocytes) was established.5

Repeated IVMPS and IA treatment (figure, A♦,•) induced ongoing remission. The patient fully recovered and continues to receive a small dose of oral prednisolone (5 mg/d). He is regularly screened (every 3 months) for re-emerging disease activity and development of secondary malignancies.6

Discussion

Development of secondary autoimmunity after alemtuzumab treatment is a well-known phenomenon and has been addressed by a strict risk management program screening especially for thrombocytopenia, thyroid, and kidney autoimmunity. Although the incidence of these disorders might have been overestimated according to postmarketing studies,2 a variety of other rare entities have been described in the past 2 years. These reports include both organ-restricted diseases and systemic conditions.3 Two additional iMCD cases have been described, with disease onset at 31 and 41 months after alemtuzumab initiation.6,7

One feature shared by HLH and iMCD is their association with different malignancies which can occur before, concurrent with, or after iMCD diagnosis (with an incidence of up to 19%). These require careful consideration when adjusting the patient's risk management plan, especially beyond 48 months after the last alemtuzumab infusion.5 Furthermore, differentiation of HLH and iMCD is crucial because the latter can be treated with the monoclonal anti-IL6 antibody siltuximab.5

In conclusion, the current case highlights iMCD as another rare but potentially life-threatening secondary autoimmune event after alemtuzumab treatment. Until risk management plans have been adjusted to include these new disorders, clinicians should perform a thorough clinical follow-up (e.g., screening of B symptoms, examination of LNs) and, in suspicious cases, seek early interdisciplinary support.

Study funding

This study was financially supported by the Competence Network Multiple Sclerosis (01GI1603D, PROGRAMMS to T. Ruck, H. Wiendl and S.G. Meuth). This study was also supported by Genzyme Therapeutics Ltd., United Kingdom (“Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential” [ALAIN01] to H. Wiendl, S.G.Meuth, and T. Ruck).

Disclosure

L. Rolfes received travel reimbursements from Merck Serono and Sanofi Genzyme. S. Pfeuffer received travel reimbursements from Sanofi Genzyme and Merck Serono; received honoraria for lecturing from Sanofi Genzyme, Biogen, and Mylan Healthcare; and received research support from Merck Serono, DiaMed, and the German Multiple Sclerosis Society. T. Ruck received travel expenses and financial research support from Genzyme and Novartis and received honoraria for lecturing from Roche, Merck, Genzyme, Biogen, and Teva. S. Windhagen, I. Oschlies, H.-J. Pavenstädt, and L. Angenendt report no disclosures. H. Wiendl received compensation for serving on Scientific Advisory Boards/Steering Committees for Bayer HealthCare, Biogen Idec, Sanofi Genzyme, Merck Serono, and Novartis; received speaker honoraria and travel support from Bayer Vital GmbH, Bayer Schering AG, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, Genzyme, Merck Serono, OmniaMed, Novartis, and Sanofi-Aventis; received compensation as a consultant from Biogen Idec, Merck Serono, Novartis, Roche, and Sanofi Genzyme; and also received research support from Bayer HealthCare, Bayer Vital, Biogen Idec, Merck Serono, Novartis, Sanofi Genzyme, Sanofi US, and Teva. J. Krämer received honoraria for lecturing from Biogen, Novartis, Mylan, and Teva and financial research support from Sanofi Genzyme. S.G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer HealthCare, Biogen, Celgene, DiaMed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, Ono Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva and his research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, Almirall, Amicus Therapeutics Germany, Biogen, DiaMed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, Ono Pharma, Roche, and Teva. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the authors.

  • ↵* These authors contributed equally to the manuscript.

  • Received June 14, 2019.
  • Accepted in final form September 6, 2019.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Coles AJ,
    2. Twyman CL,
    3. Arnold DL, et al
    . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829–1839.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Coles AJ,
    2. Cohen JA,
    3. Fox EJ, et al
    . Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 2017;89:1117–1126.
    OpenUrl
  3. 3.↵
    1. Saarela M,
    2. Senthil K,
    3. Jones J, et al
    . Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology 2018;90:849–851.
    OpenUrl
  4. 4.↵
    1. Kubokawa I,
    2. Yachie A,
    3. Hayakawa A, et al
    . The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease. BMC Pediatr 2014;14:139.
    OpenUrl
  5. 5.↵
    1. Liu AY,
    2. Nabel CS,
    3. Finkelman BS, et al
    . Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol 2016;3:e163–e175.
    OpenUrl
  6. 6.↵
    1. Somerfield J,
    2. Hill-Cawthorne GA,
    3. Lin A, et al
    . A novel strategy to reduce immunogenicity of biological therapies. J Immunol 2010;185:763–768.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Boddu PC,
    2. Hassan A,
    3. Mauer A,
    4. Singh DA,
    5. Weisenberg ES
    . Rare case of multicentric castleman disease secondary to alemtuzumab therapy. Int J Tumor Ther 2015;4:1–4.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Topics Discussed

Alert Me

Advertisement